Tatsuya Watanabe

Dr. Tatsuya Watanabe

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 June 2016 in SpringerPlus
Verified
Journal Article
Open access
PDF file
TWTatsuya Watanabe
Tatsuya Watanabe
MNMamoru Narukawa
Mamoru Narukawa
In Japan, postmarketing surveillance (PMS) studies are required for newly approved drug products to further collect safety information in clinical settings. “PMS study” is a general term encompassing both postmarketing observational (PMO) studies and postmarketing intervention studies for re-examination. Each PMS study is conducted under contracts between the pharmaceutical company and medical institutions in accordance with Good Postmarketing Study Practice. It has been reported that the safety information collected postmarketing is limited because of underreporting. The objective of this investigation was to identify differences among profiles of the drug product safety information collected through intervention studies and observational studies before and after approval. Our study addressed whether the issue of underreporting, generally considered as associated with observational studies, occurs in PMO studies for re-examination. In addition, we considered potential causes of such underreporting. The overall adverse reaction rate was lower in PMO studies than in intervention studies before approval in almost all cases. The adverse reaction rate in intervention studies exhibited similar profiles regardless of whether they were conducted prior to or following approval. In addition, we found that one reason for a lower adverse reaction rate in PMO studies was that the number of reports of adverse reactions that had occurred frequently prior to approval decreased postmarketing. Underreporting was observed even in PMO studies for re-examination under the Japanese regulation. Although it was suggested that expected and common adverse reactions were more likely to be subject to underreporting, further investigation is warranted to explore the reasons for the under-reporting in PMO studies.

2 November 2021 in Healthcare
Verified
Journal Article
Open access
PDF file
MOMiku Ogura
Miku Ogura
RTRieko Takehira
Rieko Takehira
TWTatsuya Watanabe
Tatsuya Watanabe
EAEtsuko Arita
Etsuko Arita
In recent years, the importance of building evidence in clinical practice that is increasingly acknowledged globally has been recognized in Japan as well, and it is expected that clinical research by community pharmacists will grow. In Japan, however, community pharmacists have few opportunities to learn about research ethics and may lack the training to make ethical decisions. We conducted a questionnaire survey of community pharmacists (n = 200) using a free descriptive format to understand how they perceived research ethics. Our qualitative analysis of 170 respondents revealed various perspectives (, , and ) of Japanese pharmacists on ethics in the context of clinical research. With respect to how to understand research, the following perspectives were found: “research that prioritizes researchers,” “research that prioritizes research subjects (patients),” and “research that enters into regular work.” The perspectives on “research that prioritizes research subjects (patients)” and “research that enters into regular work” may inadvertently lead to ethically inappropriate research due to mismatch in professional values or poor understanding of research. These findings can contribute to the development of an educational program for community pharmacists on research ethics.